1887

Abstract

In recent years, hospitals in southeastern Europe have faced dramatically high rates of antibiotic-resistant Acinetobacter baumannii. We analysed the evolution of resistance among clinical isolates of A. baumannii group obtained from nine tertiary hospitals throughout Greece over 6 years (2010–2015). Identification and antimicrobial susceptibility testing were performed using Vitek 2 or Microscan walkaway automated systems. Between 2010 and 2015, resistance to ampicillin/sulbactam increased from 46.2 to 88.2 % (P=0.021), resistance to gentamicin increased from 69.3 to 86.4 % (P=0.014) and resistance to tobramycin increased from 59.8 to 76.8 % (P=0.011). Imipenem resistance rates were consistently very high, ranging from 90.3 % in 2010 to 94.5 % in 2015 (P=0.198), while meropenem resistance rates increased from 82.6 % in 2010 to 94.8 % in 2015 (P=0.006). Resistance rates to trimethoprim/sulfamethoxazole showed a remarkable decreasing trend, declining from 90.2 % in 2010 to 69.1 % in 2015 (P=0.035). These evolutions render the treatment of A. baumannii infections particularly challenging and underline the need for enhanced infection control measures.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000708
2018-03-05
2019-10-16
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/4/496.html?itemId=/content/journal/jmm/10.1099/jmm.0.000708&mimeType=html&fmt=ahah

References

  1. Zarrilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents 2013;41:11–19 [CrossRef][PubMed]
    [Google Scholar]
  2. Pournaras S, Dafopoulou K, Del Franco M, Zarkotou O, Dimitroulia E et al. Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study. Int J Antimicrob Agents 2017;49:749–753 [CrossRef][PubMed]
    [Google Scholar]
  3. Dimitriadis P, Protonotariou E, Varlamis S, Poulou A, Vasilaki O et al. Comparative evaluation of minocycline susceptibility testing methods in carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2016;48:321–323 [CrossRef][PubMed]
    [Google Scholar]
  4. Vourli S, Dafopoulou K, Vrioni G, Tsakris A, Pournaras S. Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2017;72:2528–2530 [CrossRef][PubMed]
    [Google Scholar]
  5. EUCAST 2015; Breakpoint Tables for Interpretation of Mics and Zone Diameters, version 5.0 Växjö, Sweden: EUCAST Laboratory for Antimicrobial Susceptibility Testing;www.eucast.org/clinical _breakpoints/
    [Google Scholar]
  6. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Fifth Informational Supplement CLSI document M100-S25 Wayne, PA: CLSI; 2015
    [Google Scholar]
  7. European Centre for Disease Prevention and Control 2017; Antimicrobial resistance surveillance in Europe 2015. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) Stockholm, Sweden: ECDC; Available fromhttps://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-resistance-europe-2015.pdf [Accessed 11 October 2017]
    [Google Scholar]
  8. Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect 2016;22:S9–S14 [CrossRef][PubMed]
    [Google Scholar]
  9. Nepka M, Perivolioti E, Kraniotaki E, Politi L, Tsakris A et al. In vitro bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 2016;60:6903–6906 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000708
Loading
/content/journal/jmm/10.1099/jmm.0.000708
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error